Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1Blast Crisis 1Anemia, Aplastic 1Anemia 1

Interventions

Epoetin Alfa 55Darbepoetin alfa 39epoetin beta 14ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4Biopsy 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Erythrocyte Transfusion 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × CT-P10 × Classical hematology × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡